Edaravone has strong domestic demand

With clinical promotion and use, it has been proven that edaravone can inhibit the production of free radicals when patients experience cerebral ischemia and hypoxia, thereby protecting brain tissue and promoting the recovery of neurological function. Because edaravone injection is a drug included in the medical insurance catalog, it is bound to have a good market.

From 2010 to 2014, the market sales of edaravone injection in China maintained a growth trend, rising from 1.84 billion yuan in 2010 to 2.95 billion yuan in 2014. The compound annual growth rate from 2010 to 2014 reached 12.5%; the market size is expected to reach 6.5 billion yuan in 2020, with a compound annual growth rate of approximately 14.0% from 2015 to 2020.

The clinical drug market analysis of blood-based cerebral stroke neuroprotectants shows that this type of drug is still one of the hot research topics at home and abroad. Xinyao Bio has focused on drug impurity research for several years. A variety of series of drug impurity reference standards not only have high quality and good effects, but also include edaravone series impurity reference standards;
The edaravone impurities supplied by Xinyao can be used as impurity reference standards, applied to the qualitative and quantitative research and detection of edaravone raw materials and their preparations, accelerating drug research and development, assisting in consistency evaluation, and saving time and effort for pharmaceutical companies and research laboratories.

 

Edaravone is an antioxidant and free radical scavenging drug, mainly used clinically in the treatment of cerebral hemorrhage and cerebral infarction. It has a powerful free radical scavenging function and can effectively protect nerves, which is of great clinical significance for the treatment of acute cerebral infarction.

Edaravone is also currently used to inhibit the progression of functional impairment in amyotrophic lateral sclerosis (commonly known as amyotrophic lateral sclerosis, ALS). It has become the only edaravone preparation in China with both cerebral infarction and ALS indications.

Edaravone has strong domestic demand

With clinical promotion and use, it has been proven that edaravone can inhibit the production of free radicals when patients experience cerebral ischemia and hypoxia, thereby protecting brain tissue and promoting the recovery of neurological function. Because edaravone injection is a drug included in the medical insurance catalog, it is bound to have a good market.

From 2010 to 2014, the market sales of edaravone injection in China maintained a growth trend, rising from 1.84 billion yuan in 2010 to 2.95 billion yuan in 2014. The compound annual growth rate from 2010 to 2014 reached 12.5%; the market size is expected to reach 6.5 billion yuan in 2020, with a compound annual growth rate of approximately 14.0% from 2015 to 2020.

The clinical drug market analysis of blood-based cerebral stroke neuroprotectants shows that this type of drug is still one of the hot research topics at home and abroad. Xinyao Bio has focused on drug impurity research for several years. A variety of series of drug impurity reference standards not only have high quality and good effects, but also include edaravone series impurity reference standards;
The edaravone impurities supplied by Xinyao can be used as impurity reference standards, applied to the qualitative and quantitative research and detection of edaravone raw materials and their preparations, accelerating drug research and development, assisting in consistency evaluation, and saving time and effort for pharmaceutical companies and research laboratories.